THERAPY DOSSIER · th-be015766b7e5

Bone marrow-derived mesenchymal stem cells, aged versus young

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24559482 ↗2014Mixed findings

Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response.

MouseEndotoxin/LPSC57BL/6FemaleAdoptive transfer, route not stated

Model: Endotoxaemia and acute lung injury in young recipient mice with adoptive transfer of aged versus young bone marrow-derived mesenchymal stem cells; old versus young mice also compared for injury response

Aged bone marrow-derived mesenchymal stem cells lacked the anti-inflammatory protective effect seen with young cells after adoptive transfer to endotoxaemic mice, attributed to reduced cytokine and chemokine receptor expression and impaired migration.

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…